<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cardiac toxicity may be associated with drugs used for <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001664'>Torsades de pointes</z:hpo> (TdP) is a well-known adverse effect of <z:chebi fb="0" ids="28593">quinidine</z:chebi> when used for <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Intravenous <z:chebi fb="0" ids="28593">quinidine</z:chebi> doses for resistant <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> are 2 to 3 times higher than those used for <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Among 6 patients receiving <z:chebi fb="0" ids="28593">quinidine</z:chebi> for <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> or <z:e sem="disease" ids="C0004576" disease_type="Disease or Syndrome" abbrv="">babesiosis</z:e>, 4 developed QT interval prolongation and 2 experienced TdP </plain></SENT>
<SENT sid="4" pm="."><plain>Clinicians should be aware that recommended doses of <z:chebi fb="0" ids="28593">quinidine</z:chebi> for <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> carry a high TdP risk </plain></SENT>
</text></document>